Stifel reiterates Buy rating on Rhythm Pharmaceuticals stock ahead of PDUFA date

Rhythm Pharmaceuticals (RYTM) is experiencing significant positive momentum for its setmelanotide drug in Hypothalamic Obesity (HO), with the FDA granting priority review to its sNDA, targeting a December 20, 2025, decision after positive clinical data showed a 19.8% BMI reduction. Analysts have responded by raising price targets and projecting peak sales of $2.3 billion for an expanded US patient population of 10,000, despite ongoing market opportunity discussions. The company's robust commercial strategy, 89% gross margin, and upcoming Phase 2 Prader-Willi Syndrome readout further support its growth trajectory and recent 85% stock appreciation.

Analysis

Rhythm Pharmaceuticals (RYTM) is demonstrating significant progress in the clinical and regulatory pathway for its lead drug, setmelanotide, in hypothalamic obesity (HO). The company's recent investor event highlighted compelling clinical data, including a statistically significant 19.8% BMI reduction versus placebo, which has bolstered confidence in the drug's efficacy. This is further substantiated by regulatory momentum, with the FDA granting priority review to the supplemental New Drug Application (sNDA) and setting a PDUFA date of December 20, 2025, a process mirrored by validation from the European Medicines Agency. Consequently, analyst sentiment is strongly positive, with firms like Stifel, Goldman Sachs, and Morgan Stanley raising price targets—ranging up to $157—and Goldman Sachs estimating peak sales potential of $2.3 billion. The company's management has also updated its addressable market guidance to approximately 10,000 patients in the US. Financially, Rhythm appears well-capitalized to support commercialization, boasting a robust 89% gross profit margin and strong liquidity, which underpins its strategy to deploy an expanded sales force targeting 2,400 endocrinologists. The stock's 85% return over the past year reflects strong execution, with a key near-term catalyst being the upcoming Phase 2 data readout for Prader-Willi Syndrome (PWS) expected later this year.

Key Decisions for Investors

• Given the strong clinical data, a de-risked regulatory timeline for hypothalamic obesity, and upward revisions to market size and analyst price targets, the fundamental outlook for Rhythm Pharmaceuticals appears increasingly bullish.
• Investors should closely monitor the upcoming Phase 2 data readout for Prader-Willi Syndrome later this year, as it represents a significant near-term catalyst that could materially impact the stock's valuation.
• While the stock has appreciated significantly, the commercial execution following the potential 2025 approval remains a key variable; tracking early sales ramp, payer engagement, and physician adoption will be critical to validating the $2.3 billion peak sales potential.